# Clinical Study of SM3321 With Solid Tumors

> **NCT06087770** · PHASE1 · UNKNOWN · sponsor: **Beijing StarMab Biomed Technology Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** SM3321

## Key facts

- **NCT ID:** NCT06087770
- **Lead sponsor:** Beijing StarMab Biomed Technology Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-07
- **Primary completion:** 2025-08-19
- **Final completion:** 2025-10-14
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087770, "Clinical Study of SM3321 With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06087770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*